The Corrected Values for Duration and Frequency of Angina at Baseline in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial (DOI:10.1016/j.amjcard.2006.07.082);The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial

American Journal of Cardiology

Volumn 99, Issue 2, 2007, Pages 208-212

  Boden, William E ^a   O'Rourke, Robert A ^c   Teo, Koon K ^d   Hartigan, Pamela M ^b   Maron, David J ^h   Kostuk, William ^e   Knudtson, Merril ^f   Dada, Marcin ^a   Casperson, Paul ^c   Harris, Crystal L ⁱ   Spertus, John A ^j   Shaw, Leslee ^l   Chaitman, Bernard R ^k   Mancini, G B John ^g   Berman, Daniel S ^l   Gau, Gerald ^m   Weintraub, William S ⁿ  

^a HARTFORD HOSPITAL   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f FOOTHILLS HOSPITAL   (Canada)

^g VANCOUVER GENERAL HOSPITAL   (Canada)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^k SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m MAYO CLINIC   (United States)

ⁿ CHRISTIANA CARE HEALTH SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN II ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; NITRATE; VITAMIN; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DYSLIPIDEMIA; EVALUATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SEX RATIO; SMOKING; TREATMENT OUTCOME; UNITED STATES;

EID: 33846061088     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.009     Document Type: Erratum

References (20)

1. Parisi A.F., Folland E.D., and Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 326 (1992) 10-16
2. Folland E.D., Hartigan P.M., and Parisi A.F. Percutaneous transluminal coronary angioplasty (PTCA) compared to medical therapy for stable angina pectoris: outcomes for patients with double vessel compared to single vessel coronary artery disease in a randomized VA cooperative study. J Am Coll Cardiol 29 (1997) 1505-1511
3. RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: the second Randomized Intervention Treatment of Angina (RITA-2) trial. Lancet 350 (1997) 461-469
4. Henderson R.A., Pocock S.J., Clayton T.C., Knight R., Fox K.A., Julian D.G., Chamberlain D.A., and Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 42 (2003) 1161-1170
5. Hueb W.A., Bellotti G., de Oliveira S.A., Arie S., Cardoso R.H., Wajsbrot D.A., Cesar L.A., Jatene A.D., and Ramires J.A. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 26 (1995) 1600-1605
6. Hueb W., Soares P.R., Gersh B.J., Cesar L.A., Luz P.L., Puig L.B., Martinez E.M., Oliveira S.A., and Ramires J.A. The Medicine, Angioplasty, or Surgery Study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 43 (2004) 1743-1751
7. Pitt B., Waters D., Brown W.V., van Boven A.J., Schwartz L., Title L.M., Eisenberg D., Shurzinske L., and McCormick L.S. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin Versus Revascularization Treatment Investigators. N Engl J Med 341 (1999) 70-76
8. Yusuf S., Wittes J., and Friedman L. Overview of results of randomized clinical trials in heart disease I. Treatments following myocardial infarction. JAMA 260 (1988) 2088-2093
9. Beta Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247 (1982) 1707-1714
10. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., and Flaker G.C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
11. The SOLVD Investigators. Effect of angiotensin converting enzyme inhibitor enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325 (1991) 293-302
12. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor,ramipril,on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
13. Fox K.M., and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 362 (2003) 782-788
14. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., and Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
15. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J., and CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 288 (2002) 2411-2420
16. Boden W.E., O'Rourke R.A., Koon K.K., Hartigan P.M., Maron D.J., Kostuk W., Knudtson M., Dada M., Casperson P., Harris C.L., et al., COURAGE Trial Co-principal Investigators and Study Coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial VA Cooperative Studies Program 424. Am Heart J 151 (2006) 1173-1179
17. Ryan T.J., Bauman W.B., Kennedy J.W., Kereiakes D.J., King III S.B., McCallister B.D., Smith Jr. S.C., and Ullyot D.J. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 88 (1993) 2987-3007
18. Grundy S.M., Brewer H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C., American Heart Association; National Heart, and Lung and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109 (2004) 433-438
19. Bhatt D.L., Fox K.A.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., et al., CHARISMA Investigators. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 150 suppl (2005) 401 e1-401.e7
20. Bhatt D.L., Fox K.A.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717